Novartis Q4 Results
Content
Click below to navigate
through the document
CoartemⓇ - PGH-1 (artemisinin combination therapy)
↓
↑
Company overview
Financial review
Conclusions
NCT04300309 CALINA (CCOA566B2307)
Malaria, uncomplicated (<5kg patients)
Phase 3
Indication
Phase
Patients
44
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
Oncology
Other
> Global Health
Abbreviations
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Artemether Cmax
Experimental: artemether lumefantrine (2.5 mg:30 mg)
artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium
falciparum malaria
Primary (actual) 2024 (final)
Readout
Milestone(s)
Publication
TBD
References
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
83View entire presentation